Myasthenia Gravis - Pipeline Review, H2 2017

Date: July 18, 2017
Pages: 122
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until September 1, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M5A35F8A463EN
Leaflet:

Download PDF Leaflet

Myasthenia Gravis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H2 2017, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 4, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Myasthenia Gravis - Overview
Myasthenia Gravis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myasthenia Gravis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myasthenia Gravis - Companies Involved in Therapeutics Development
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Apellis Pharmaceuticals Inc
arGEN-X BV
BioMarin Pharmaceutical Inc
Bristol-Myers Squibb Company
CuraVac Inc
GlaxoSmithKline Plc
Grifols SA
HanAll Biopharma Co Ltd
Millennium Pharmaceuticals Inc
Neurotune AG
Novartis AG
Pfizer Inc
Ra Pharmaceuticals Inc
Regenesance BV
Shire Plc
Toleranzia AB

UCB SA

Myasthenia Gravis - Drug Profiles
abatacept - Drug Profile
ACT-101 - Drug Profile
amifampridine phosphate - Drug Profile
APL-2 - Drug Profile
belimumab - Drug Profile
bortezomib - Drug Profile
CFZ-533 - Drug Profile
CVMG-01 - Drug Profile
eculizumab - Drug Profile
efgartigimod alfa - Drug Profile
GL-2045 - Drug Profile
HL-161 - Drug Profile
immune globulin (human) - Drug Profile
methotrexate - Drug Profile
NT-1654 - Drug Profile
RA-101495 - Drug Profile
Recombinant Protein for Myasthenia Gravis - Drug Profile
Recombinant Protein to Target CHRNA1 for Myasthenia Gravis - Drug Profile
Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile
Regenemab - Drug Profile
rozanolixizumab - Drug Profile
SM-201 - Drug Profile
Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis - Drug Profile
Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
TK-21 - Drug Profile
Vaccine for Myasthenia Gravis - Drug Profile
Vaccine for Myasthenia Gravis - Drug Profile
Myasthenia Gravis - Dormant Projects
Myasthenia Gravis - Discontinued Products
Myasthenia Gravis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Myasthenia Gravis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Myasthenia Gravis - Pipeline by Achillion Pharmaceuticals Inc, H2 2017
Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H2 2017
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H2 2017
Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H2 2017
Myasthenia Gravis - Pipeline by Apellis Pharmaceuticals Inc, H2 2017
Myasthenia Gravis - Pipeline by arGEN-X BV, H2 2017
Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H2 2017
Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Company, H2 2017
Myasthenia Gravis - Pipeline by CuraVac Inc, H2 2017
Myasthenia Gravis - Pipeline by GlaxoSmithKline Plc, H2 2017
Myasthenia Gravis - Pipeline by Grifols SA, H2 2017
Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H2 2017
Myasthenia Gravis - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Myasthenia Gravis - Pipeline by Neurotune AG, H2 2017
Myasthenia Gravis - Pipeline by Novartis AG, H2 2017
Myasthenia Gravis - Pipeline by Pfizer Inc, H2 2017
Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H2 2017
Myasthenia Gravis - Pipeline by Regenesance BV, H2 2017
Myasthenia Gravis - Pipeline by Shire Plc, H2 2017
Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2017
Myasthenia Gravis - Pipeline by UCB SA, H2 2017
Myasthenia Gravis - Dormant Projects, H2 2017
Myasthenia Gravis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Myasthenia Gravis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Skip to top


Myasthenia Gravis Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 76 pages

Ask Your Question

Myasthenia Gravis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: